Explore

Trendline Trendline
PharmaResearch Gains FDA Approval for Phase 1 Trial of Nano Anticancer Drug PRD-101

PharmaResearch Gains FDA Approval for Phase 1 Trial of Nano Anticancer Drug PRD-101

PharmaResearch Gains FDA Approval for Phase 1 Trial of Nano Anticancer Drug PRD-101
Trendline Trendline
Insilico Medicine Achieves Milestone with AI-Designed Drug in Human Trials

Insilico Medicine Achieves Milestone with AI-Designed Drug in Human Trials

Insilico Medicine Achieves Milestone with AI-Designed Drug in Human Trials
Trendline Trendline
K36 Therapeutics Completes Initial Dosing in Prostate Cancer Trial, Appoints New CMO

K36 Therapeutics Completes Initial Dosing in Prostate Cancer Trial, Appoints New CMO

K36 Therapeutics Completes Initial Dosing in Prostate Cancer Trial, Appoints New CMO
Rapid Read Rapid Read
Experimental Pill Enlicitide Shows Promise in Reducing LDL Cholesterol

Experimental Pill Enlicitide Shows Promise in Reducing LDL Cholesterol

A new experimental pill, enlicitide, has demonstrated the ability to reduce LDL cholesterol levels by up to 60% in a phase three clinical trial. The study, published in the New England Journal of Medicine, involved 2,909 patients with atherosclerosis or at risk of developing it. Despite most participants already taking statins, enlicitide significantly lowered their LDL cholesterol levels. The trial was led by Dr. Ann Marie Navar at UT Southwestern Medical Center and sponsored by Merck & Co. Inc. The pill works by binding to PCSK9 in the bloodstream, offering a convenient oral alternative to existing injectable therapies.
Trendline Trendline
Deep Learning Model Developed to Predict Functional Impact of Regulatory Mutations

Deep Learning Model Developed to Predict Functional Impact of Regulatory Mutations

Deep Learning Model Developed to Predict Functional Impact of Regulatory Mutations
Trendline Trendline
Insilico Medicine Achieves Milestone with AI-Designed Drug in Clinical Trials

Insilico Medicine Achieves Milestone with AI-Designed Drug in Clinical Trials

Insilico Medicine Achieves Milestone with AI-Designed Drug in Clinical Trials
Rapid Read Rapid Read
Quebec's Public Reimbursement of Jemperli Plus Chemotherapy Expands Access for Endometrial Cancer Patients

Quebec's Public Reimbursement of Jemperli Plus Chemotherapy Expands Access for Endometrial Cancer Patients

Quebec has become the first Canadian province to publicly reimburse Jemperli (dostarlimab for injection) in combination with chemotherapy for treating adult patients with primary advanced or first recurrent endometrial cancer. This decision, announced by GSK, marks a significant milestone in improving access to treatment for eligible patients. The reimbursement is facilitated through the Régie de l'assurance maladie du Québec (RAMQ), removing financial barriers and enabling timely access to this standard-of-care combination therapy. The decision follows Health Canada's approval of the indication in April 2025, based on the RUBY phase III trial results, which demonstrated significant survival benefits. This move is expected to set a positive precedent for other provinces in Canada.
Trendline Trendline
Anixa Biosciences Gains USAN Approval for CAR-T Therapy, Paving Way for Commercialization

Anixa Biosciences Gains USAN Approval for CAR-T Therapy, Paving Way for Commercialization

Anixa Biosciences Gains USAN Approval for CAR-T Therapy, Paving Way for Commercialization
Trendline Trendline
Immuneering's New Cancer Drug Focuses on Quality of Life for Patients

Immuneering's New Cancer Drug Focuses on Quality of Life for Patients

Immuneering's New Cancer Drug Focuses on Quality of Life for Patients
Rapid Read Rapid Read
Researchers Develop Genetic Blueprint to Combat T Cell Exhaustion in Cancer Therapy

Researchers Develop Genetic Blueprint to Combat T Cell Exhaustion in Cancer Therapy

A multi-institutional study led by researchers from the UNC Lineberger Comprehensive Cancer Center, the Salk Institute for Biological Studies, and UC San Diego has identified new genetic mechanisms that influence the state of CD8+ killer T cells. These cells are crucial for immune defense, targeting virus-infected and cancer cells. However, they can become ineffective in chronic infections or tumors, entering a state known as T cell exhaustion. The study, published in Nature, outlines a detailed atlas of CD8+ T cell states, revealing how these cells transition from protective to dysfunctional states. By manipulating specific genetic switches, researchers found they could restore the tumor-killing function of T cells without compromising their long-term immune memory. This discovery has significant implications for improving immunotherapy and infectious disease research.
Rapid Read Rapid Read
George Coukos Appointed Director of Ludwig Laboratory for Cell Therapy, Advancing Cancer Immunotherapy

George Coukos Appointed Director of Ludwig Laboratory for Cell Therapy, Advancing Cancer Immunotherapy

The Ludwig Institute for Cancer Research has announced the establishment of the Ludwig Laboratory for Cell Therapy at Weill Cornell Medicine, led by Dr. George Coukos. Dr. Coukos, a renowned expert in tumor immunology and cellular immunotherapy, returns to the U.S. after a transformative tenure in Switzerland. His leadership is expected to advance the development of cellular-based cancer therapies, focusing on personalized treatments for various malignancies. The laboratory aims to enhance the specificity and potency of immune cells used in cancer treatment, addressing challenges like tumor heterogeneity and immunosuppressive environments.
Rapid Read Rapid Read
New Cholesterol-Lowering Pill Enlicitide Shows Promising Results in Clinical Trial

New Cholesterol-Lowering Pill Enlicitide Shows Promising Results in Clinical Trial

A new experimental pill, enlicitide, has demonstrated significant potential in reducing artery-clogging cholesterol levels in patients who are at high risk of heart attacks, despite already taking statins. According to a study published in the New England Journal of Medicine, enlicitide was tested on over 2,900 high-risk patients, resulting in a reduction of LDL cholesterol by up to 60% over six months. This pill offers an alternative to the current PCSK9 inhibitor injections, which are less favored due to their complexity and the discomfort of administration. The study, funded by Merck, indicates that enlicitide could become a more accessible option for patients if approved by the U.S. Food and Drug Administration (FDA). The FDA has already included the drug in a program for ultra-fast reviews, suggesting a potential for quicker availability to the public.